Therapy News and Research

RSS

Study compares two radiation therapy techniques available to women with breast cancer

Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), according to researchers from The University of Texas MD Anderson Cancer Center.

7 Dec 2011

King's College London submits first clinical grade xeno-free hES cell lines to the UKSCB

Stem cell scientists at King's College London will announce they have submitted to the UK Stem Cell Bank (UKSCB) their first clinical grade human embryonic stem (hES) cell lines that are free from animal-derived products, known as 'xeno-free' stem cells.

7 Dec 2011

Combination of cannabinoids and opiates could help reduce chronic pain

A UCSF study suggests patients with chronic pain may experience greater relief if their doctors add cannabinoids - the main ingredient in cannabis or medical marijuana - to an opiates-only treatment. The findings, from a small-scale study, also suggest that a combined therapy could result in reduced opiate dosages.

7 Dec 2011

Breast reconstruction after mastectomy safe for older women

Breast cancer is on the rise and 48 percent of all breast cancers occur in women older than 65, but very few of them choose to have breast reconstruction. A new study from Wake Forest Baptist Medical Center sought to determine if breast reconstruction after mastectomy is safe for older women. The answer is yes.

7 Dec 2011

Fake, poor-quality drugs boosting malaria drug resistance in Southeast Asia, U.S. experts say

"Fake or poor quality malaria drugs are boosting resistance in parts of southeast Asia, a problem that is likely to worsen unless tighter regulations are adopted, U.S. experts said Monday" at a hearing of the House Foreign Affairs Subcommittee on Africa, Global Health, and Human Rights, Agence France-Presse reports.

7 Dec 2011

TAU develops tumor destruction method that also creates immunity

Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal.

7 Dec 2011

Milk powder outperforms lower-dose therapy for treatment of food allergies

A small study by researchers at the Johns Hopkins Children's Center and Duke University shows that eating higher doses of milk protein in the form of dry powder substantially outperforms lower-dose therapy — a few drops of liquid milk extract under the tongue — for treatment of food allergies.

7 Dec 2011

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

Hormone-blocking therapy for prostate cancer doesn't raise the risk of fatal heart attacks - as some recent studies had suggested - according to a new report from Dana-Farber/Brigham and Women's Cancer Center.

7 Dec 2011

Mayo Clinic in Florida now offers kidney and pancreas transplants for HIV-positive patients

Mayo Clinic in Florida is now offering kidney and pancreas transplants to HIV positive patients with advanced kidney disease and diabetes. Evidence is now solid that HIV-positive patients have the same favorable outcome in terms of patient and allograft survival as non-HIV positive organ transplant recipients, says Mary Prendergast, M.D., a kidney specialist whose focus is the care of patients who receive kidney and pancreas transplants.

7 Dec 2011

Therakos commences enrollment in photopheresis Phase IIb clinical study for chronic GvHD

Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).

6 Dec 2011

Landauer fourth quarter revenue increases 5.3% to $120.5 million

Landauer, Inc., a recognized leader in personal and environmental radiation monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2011 fourth quarter and year ended September 30, 2011.

6 Dec 2011

Xeltis receives PEI conditional approval to initiate tissue-engineered cardiovascular graft study

Xeltis, a biomedical technology company developing growing, living and self-healing cardiovascular implants using tissue-engineering technology, has announced conditional approval by the Paul Erlich Institute (PEI) in Germany to commence the first clinical study of its tissue-engineered cardiovascular grafts.

6 Dec 2011

GE Healthcare, UCSF collaborate for cord blood project

UCSF and the Cell Technologies business of GE Healthcare Life Sciences have begun a unique collaboration aimed at overcoming the lack of blood-forming stem cells available to patients suffering from life-threatening diseases such as lymphoma, myeloma, leukemia or sickle cell anemia.

6 Dec 2011

Breast cancer patients might experience prolonged fatigue years after chemotherapy

In a follow-up study, researchers at Moffitt Cancer Center and colleagues have found that patients who receive chemotherapy for breast cancer might experience prolonged fatigue years after their therapy.

6 Dec 2011

MHI cardiologists use ABSORB bioresorbable vascular scaffold to treat CAD

The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean-Fran-ois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial.

6 Dec 2011

FDA assigns CTIs' pixantrone NDA new PDUFA action date

Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration's Division of Oncology Products 1 has notified CTI that CTI's October 2011 resubmitted New Drug Application is considered a complete, Class 2 response to the FDA's April 2010 complete response letter.

6 Dec 2011

Aspirin decreases risk of major complications from cardiac surgery

Aspirin taken within five days of cardiac surgery is associated with a significant decrease in the risk of major postoperative complications, including renal failure, a lengthy intensive care unit stay and even early death (30-day mortality), according to a study by researchers at Thomas Jefferson University and UC Davis Medical Center set to appear in the journal Annals of Surgery.

6 Dec 2011

Stem cells for the damaged heart

Stem cell research got its latest boost. For the first time, stem cells were injected into the hearts of humans who had suffered serious heart damage, and patients improved dramatically. The scientists found that the stem cells grew into new heart cells to replace the damaged tissue.

5 Dec 2011

Veterans' access to mental health services remains a concern

Access questions and concerns are deepening as more men and women end their tours of duty and need therapy upon returning to the U.S. In other news, NPR reports on the debate surrounding the costs of military retiree benefits.

5 Dec 2011

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

5 Dec 2011

Therapy News and Research

Study compares two radiation therapy techniques available to women with breast cancer

King's College London submits first clinical grade xeno-free hES cell lines to the UKSCB

Combination of cannabinoids and opiates could help reduce chronic pain

Breast reconstruction after mastectomy safe for older women

Fake, poor-quality drugs boosting malaria drug resistance in Southeast Asia, U.S. experts say

TAU develops tumor destruction method that also creates immunity

Milk powder outperforms lower-dose therapy for treatment of food allergies

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

Mayo Clinic in Florida now offers kidney and pancreas transplants for HIV-positive patients

Therakos commences enrollment in photopheresis Phase IIb clinical study for chronic GvHD

Landauer fourth quarter revenue increases 5.3% to $120.5 million

Xeltis receives PEI conditional approval to initiate tissue-engineered cardiovascular graft study

GE Healthcare, UCSF collaborate for cord blood project

Breast cancer patients might experience prolonged fatigue years after chemotherapy

MHI cardiologists use ABSORB bioresorbable vascular scaffold to treat CAD

FDA assigns CTIs' pixantrone NDA new PDUFA action date

Aspirin decreases risk of major complications from cardiac surgery

Stem cells for the damaged heart

Veterans' access to mental health services remains a concern

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News